Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Kattenhorn

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Virology|November 25, 2005
A deubiquitinating activity is conserved in the large tegument protein of the herpesviridaeChristian Schlieker, Gregory A Korbel, Lisa M Kattenhorn, et al.
Journal of Virology|May 30, 2006
High-molecular-weight protein (pUL48) of human cytomegalovirus is a competent deubiquitinating protease: mutant viruses altered in its active-site cysteine or histidine are viableJianlei Wang, Amy N Loveland, Lisa M Kattenhorn, et al.
Molecular Cell|March 14, 2007
Structure of a herpesvirus-encoded cysteine protease reveals a unique class of deubiquitinating enzymesChristian Schlieker, Wilhelm A Weihofen, Evelyne Frijns, et al.
Molecular Cell|August 20, 2005
A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family HerpesviridaeLisa M Kattenhorn, Gregory A Korbel, Benedikt M Kessler, et al.
Journal of Virology|September 29, 2004
Identification of proteins associated with murine cytomegalovirus virionsLisa M Kattenhorn, Ryan Mills, Markus Wagner, et al.
Human Gene Therapy|November 30, 2016
Adeno-Associated Virus Gene Therapy for Liver DiseaseLisa M Kattenhorn, Christopher H Tipper, Lorelei Stoica, et al.
Toxicologic Pathology|October 18, 2021
Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus VectorsJulie A Hutt, Basel T Assaf, Brad Bolon, et al.
Molecular Therapy. Methods & Clinical Development|December 10, 2016
Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaquesJenny A Greig, Jayme Ml Nordin, Erin Bote, et al.
Human Gene Therapy|October 15, 2021
Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia AJenny A Greig, Melanie K Smith, Jayme M L Nordin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 2, 2019
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing AntibodiesMatthew R Gardner, Ina Fetzer, Lisa M Kattenhorn, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Virology|November 25, 2005
A deubiquitinating activity is conserved in the large tegument protein of the herpesviridaeChristian Schlieker, Gregory A Korbel, Lisa M Kattenhorn, et al.
Journal of Virology|May 30, 2006
High-molecular-weight protein (pUL48) of human cytomegalovirus is a competent deubiquitinating protease: mutant viruses altered in its active-site cysteine or histidine are viableJianlei Wang, Amy N Loveland, Lisa M Kattenhorn, et al.
Molecular Cell|March 14, 2007
Structure of a herpesvirus-encoded cysteine protease reveals a unique class of deubiquitinating enzymesChristian Schlieker, Wilhelm A Weihofen, Evelyne Frijns, et al.
Molecular Cell|August 20, 2005
A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family HerpesviridaeLisa M Kattenhorn, Gregory A Korbel, Benedikt M Kessler, et al.
Journal of Virology|September 29, 2004
Identification of proteins associated with murine cytomegalovirus virionsLisa M Kattenhorn, Ryan Mills, Markus Wagner, et al.
Human Gene Therapy|November 30, 2016
Adeno-Associated Virus Gene Therapy for Liver DiseaseLisa M Kattenhorn, Christopher H Tipper, Lorelei Stoica, et al.
Toxicologic Pathology|October 18, 2021
Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus VectorsJulie A Hutt, Basel T Assaf, Brad Bolon, et al.
Molecular Therapy. Methods & Clinical Development|December 10, 2016
Impact of intravenous infusion time on AAV8 vector pharmacokinetics, safety, and liver transduction in cynomolgus macaquesJenny A Greig, Jayme Ml Nordin, Erin Bote, et al.
Human Gene Therapy|October 15, 2021
Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia AJenny A Greig, Melanie K Smith, Jayme M L Nordin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 2, 2019
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing AntibodiesMatthew R Gardner, Ina Fetzer, Lisa M Kattenhorn, et al.
Pageof 2